Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

Globe Newswire28 Oct 2026, 11:00 PKTvia NewsData.io

Basel, 28 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides a reliable, highly specific diagnostic tool to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell lung cancer (NSCLC). The BAP1 assay is registered as a Class I IVD with U.S. Food and Drug Administration, has received IVDR approval as a Class C device, and is available globally.

Read the full story on Globe Newswire

Headline and summary provided via NewsData.io. The full article and its copyright belong to the original publisher.